Figure 5.

Prediction of erlotinib sensitivity in NSCLC patients. (a) Months-to-progression plotted against predicted probability of erlotinib sensitivity. All patients are EGFR wild-type. KRAS mutations are highlighted and a linear regression line is shown. (b) The predicted probability of sensitivity to erlotinib plotted against months-to-progression for individuals treated with sorafenib. NSCLC, non-small cell lung cancer.

Geeleher et al. Genome Biology 2014 15:R47   doi:10.1186/gb-2014-15-3-r47
Download authors' original image